Roche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
List view / Grid view
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
The assets Roche will gain rights to through its planned acquisition of Carmot Therapeutics include several incretin treatments with best-in-class potential in obesity and diabetes.